http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 10:17:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Kazia+Therapeutics+%28KZIA%29+PT+Raised+to+%2440+at+BTIG/27010644.html <p>BTIG analyst Kambiz Yazdi raised the price target on Kazia Therapeutics (NASDAQ: KZIA) to $40.00 (from $34.00) while maintaining a Buy rating.</p><p>The analyst comments "Paxalisib showed an 83% ORR and 100% CBR across six evaluable metastatic TNBC patients, including one complete response and activity across multiple metastatic sites, including CNS lesions. While the sample size is small, the breadth of activity and biomarker data are notable, with all six patients showing reductions in terminally exhausted CD8+ T cells and CTC clusters, supporting both PI3K pathway engagement and a possible immune-restorative effect. Kazia reported no paxalisib-related serious adverse events and no http://www.streetinsider.com/Analyst+PT+Change/Kazia+Therapeutics+%28KZIA%29+PT+Raised+to+%2440+at+BTIG/27010644.html Tue, 01 Sep 2026 10:17:11 -0400 KZIA http://www.streetinsider.com/Analyst+Comments/Kazia+Therapeutics+%28KZIA%29+PT+Raised+to+%2440+at+BTIG/27010644.html <p>BTIG analyst Kambiz Yazdi raised the price target on Kazia Therapeutics (NASDAQ: KZIA) to $40.00 (from $34.00) while maintaining a Buy rating.</p><p>The analyst comments "Paxalisib showed an 83% ORR and 100% CBR across six evaluable metastatic TNBC patients, including one complete response and activity across multiple metastatic sites, including CNS lesions. While the sample size is small, the breadth of activity and biomarker data are notable, with all six patients showing reductions in terminally exhausted CD8+ T cells and CTC clusters, supporting both PI3K pathway engagement and a possible immune-restorative effect. Kazia reported no paxalisib-related serious adverse events and no http://www.streetinsider.com/Analyst+Comments/Kazia+Therapeutics+%28KZIA%29+PT+Raised+to+%2440+at+BTIG/27010644.html Tue, 01 Sep 2026 10:17:11 -0400 KZIA http://www.streetinsider.com/Corporate+News/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html <p>Kazia Therapeutics (NASDAQ: KZIA) announced preclinical data showing its drug paxalisib reduced tumor burden by 52% in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer models, according to a company statement.</p><p>In a separate preclinical study, adding paxalisib to pembrolizumab, an existing immunotherapy drug, reduced tumor volume by an additional 50% compared with pembrolizumab alone. The company reported no evidence of treatment-related toxicity across both studies.</p><p>MSS/pMMR colorectal cancer accounts for approximately 85–90% of metastatic colorectal cancer cases. Published clinical data indicate that checkpoint inhibitor monotherapy has provided little to no clinical benefit in this patient population.</p><p>Kazia is also developing http://www.streetinsider.com/Corporate+News/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html Tue, 01 Sep 2026 07:33:54 -0400 KVIA KZIA http://www.streetinsider.com/Corporate+News/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html <p>Kazia Therapeutics (NASDAQ: KZIA) announced preclinical data showing its drug paxalisib reduced tumor burden by 52% in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer models, according to a company statement.</p><p>In a separate preclinical study, adding paxalisib to pembrolizumab, an existing immunotherapy drug, reduced tumor volume by an additional 50% compared with pembrolizumab alone. The company reported no evidence of treatment-related toxicity across both studies.</p><p>MSS/pMMR colorectal cancer accounts for approximately 85–90% of metastatic colorectal cancer cases. Published clinical data indicate that checkpoint inhibitor monotherapy has provided little to no clinical benefit in this patient population.</p><p>Kazia is also developing http://www.streetinsider.com/Corporate+News/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html Tue, 01 Sep 2026 07:33:54 -0400 KVIA KZIA http://www.streetinsider.com/FDA/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html <p>Kazia Therapeutics (NASDAQ: KZIA) announced preclinical data showing its drug paxalisib reduced tumor burden by 52% in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer models, according to a company statement.</p><p>In a separate preclinical study, adding paxalisib to pembrolizumab, an existing immunotherapy drug, reduced tumor volume by an additional 50% compared with pembrolizumab alone. The company reported no evidence of treatment-related toxicity across both studies.</p><p>MSS/pMMR colorectal cancer accounts for approximately 85–90% of metastatic colorectal cancer cases. Published clinical data indicate that checkpoint inhibitor monotherapy has provided little to no clinical benefit in this patient population.</p><p>Kazia is also developing http://www.streetinsider.com/FDA/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html Tue, 01 Sep 2026 07:33:54 -0400 KVIA KZIA http://www.streetinsider.com/FDA/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html <p>Kazia Therapeutics (NASDAQ: KZIA) announced preclinical data showing its drug paxalisib reduced tumor burden by 52% in microsatellite stable (MSS) / proficient mismatch repair (pMMR) colorectal cancer models, according to a company statement.</p><p>In a separate preclinical study, adding paxalisib to pembrolizumab, an existing immunotherapy drug, reduced tumor volume by an additional 50% compared with pembrolizumab alone. The company reported no evidence of treatment-related toxicity across both studies.</p><p>MSS/pMMR colorectal cancer accounts for approximately 85–90% of metastatic colorectal cancer cases. Published clinical data indicate that checkpoint inhibitor monotherapy has provided little to no clinical benefit in this patient population.</p><p>Kazia is also developing http://www.streetinsider.com/FDA/Kazia+reports+paxalisib+data+in+colorectal+cancer%2C+plans+Phase+2+trial/27008900.html Tue, 01 Sep 2026 07:33:54 -0400 KVIA KZIA http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) has priced a tranched registered public offering of 2,580,000 American Depositary Shares (ADSs) at $15.50 per ADS, with expected gross proceeds of approximately $40 million before underwriting discounts and other expenses, according to a press release.</p> <p>The offering also includes two series of accompanying warrants. Series A Warrants allow the purchase of up to 2,243,478 ADSs at $17.825 each, expiring 30 days after the company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or five years from issuance, whichever comes first. Series B Warrants allow the purchase of up http://www.streetinsider.com/Equity+Offerings/Kazia+prices+public+offering+at+%2415.50+per+ADS%2C+eyes+%2440M+in+proceeds/26993059.html Fri, 28 Aug 2026 07:30:18 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <u><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></u> (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary Shares ("ADSs"), each representing five hundred (500) ordinary shares of the Company, no par value per share, or in lieu of ADSs to certain investors, pre-funded warrants to purchase ADSs, (ii) accompanying Series A Warrants to purchase up to 2,243,478 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Limited+Announces+Pricing+of+Up+to+%24120+Million+Public+Offering/26993056.html Fri, 28 Aug 2026 07:30:00 -0400 A.01902927 A.14185667 A.26693277 A.36817542 KZIA O.00073507 O.00673961 O.21906544 O.22066148 O.25213119